Ph1b/2 Study of the Safety and Efficacy of T-DXd Combinations in Advanced HER2-expressing Gastric Cancer (DESTINY-Gastric03)
A phase 2 trial of Fluorouracil (5-FU), Capecitabine, Durvalumab, Oxaliplatin, Trastuzumab and Trastuzumab deruxtecan in gastric & gastro-oesophageal junction cancer, run by AstraZeneca, active and no longer recruiting.
Overview
Ph1b/2 Study of the Safety and Efficacy of T-DXd Combinations in Advanced HER2-expressing Gastric Cancer (DESTINY-Gastric03) is a phase 2 interventional study registered as NCT04379596 by AstraZeneca, with 452 participants enrolled, started 2020-06-03 and due to reach its primary completion in 2027-05-04. Interventions recorded: Fluorouracil (5-FU), Capecitabine, Durvalumab, Oxaliplatin, Trastuzumab and Trastuzumab deruxtecan.
Similar pages
not linked directly; found by shared links- TrialA Phase Ⅲ Study of Rilvegostomig in Combination With Fluoropyrimidine and Trastuzumab Deruxtecan as the First-line Treatment for HER2-positive Gastric Cancer
Shares Capecitabine, Trastuzumab, Trastuzumab deruxtecan, AstraZeneca and the tag pipeline.
- TrialA Study of T-DXd as Monotherapy or in Combination With Anti-cancer Agents in Patients With Selected HER2-expressing Tumors
Shares Daiichi Sankyo, Trastuzumab deruxtecan, AstraZeneca, Gastric & gastro-oesophageal junction cancer and the tag pipeline.
- TrialStudy of TDXd, Chemotherapy, Pembrolizumab, and Trastuzumab in First-Line Metastatic HER2-Positive Gastric or Gastroesophageal Junction Cancer
Shares Daiichi Sankyo, Trastuzumab, Trastuzumab deruxtecan, Gastric & gastro-oesophageal junction cancer and the tag pipeline.
- TrialA Study of RC48-ADC Combination Therapies as First-line Treatment in Advanced Metastatic Gastric Cancer
Shares Oxaliplatin, Capecitabine, Trastuzumab, Gastric & gastro-oesophageal junction cancer and the tag pipeline.
- TrialA Study to Evaluate Efficacy and Safety of Tislelizumab Plus Chemotherapy for Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Adenocarcinoma and Esophageal Squamous Cell Carcinoma in Racial and Ethnic Minority Patients in the United States
Shares Fluorouracil (5-FU), Oxaliplatin, Capecitabine, Gastric & gastro-oesophageal junction cancer and the tag pipeline.
- TrialA Study of Novel Agents or Combinations as Perioperative Treatment in Participants With Locally Advanced Resectable Gastroesophageal Adenocarcinoma
Shares Fluorouracil (5-FU), Capecitabine, Trastuzumab, Trastuzumab deruxtecan and the tag pipeline.
- TrialA Phase 1b/2 Study of T-DXd Combinations in HER2-positive Metastatic Breast Cancer
Shares Daiichi Sankyo, Durvalumab, Trastuzumab deruxtecan, AstraZeneca and the tag pipeline.
- TrialA Study of Zolbetuximab Together With Pembrolizumab and Chemotherapy in Adults With Gastric Cancer
Shares Fluorouracil (5-FU), Oxaliplatin, Capecitabine, Gastric & gastro-oesophageal junction cancer and the tag pipeline.